Shilajit And Cholesterol: What The Trials Measured

Last reviewed: October 28, 2026 · By Dr. Ekta Gupta · Evidence tier labels apply on every claim (see our editorial policy)

If you've been searching for information on shilajit cholesterol effects, you've probably encountered a spectrum of claims — some measured, some wildly overstated. Let's be direct from the outset: shilajit is not a replacement for statins, it will not reverse established cardiovascular disease, and no trial has yet demonstrated that it meaningfully reduces LDL cholesterol in isolation. What the published literature does suggest is more nuanced — and arguably more interesting.

Across a small but growing body of human and animal trials, purified shilajit has been associated with modest shifts in lipid panel markers, hepatic fat metabolism, and oxidative stress pathways that intersect with cardiovascular risk. Understanding what those trials actually measured — and what they did not — is the purpose of this article.

What Is Shilajit and Why Would It Affect Lipid Metabolism?

Before examining the cholesterol-specific data, it helps to understand the mechanism by which shilajit could plausibly influence lipid profiles at all. Shilajit is a complex resinous exudate that forms over centuries as plant matter decomposes under high-altitude geological pressure. Its primary bioactive components include fulvic acid, dibenzo-alpha-pyrones (DBPs), humic acids, and a broad spectrum of trace minerals.

If you want a more complete background on what this substance actually is, the what is shilajit guide on this site covers the geology, composition, and traditional use in considerably more detail. For our purposes here, the relevant mechanism is this:

• Fulvic acid has demonstrated antioxidant and anti-inflammatory properties that may modulate lipid peroxidation — a key driver of LDL oxidation and atherogenesis [Mechanism]
• Dibenzo-alpha-pyrones appear to support mitochondrial electron transport, potentially influencing energy substrate utilization and fat metabolism [Mechanism]
• Hepatic effects are relevant because the liver is the primary site of cholesterol synthesis, esterification, and lipoprotein packaging [Mechanism]

None of these mechanisms are speculative in isolation — each has been documented in the phytochemical literature. What remains debated is whether the concentrations achievable through oral supplementation are sufficient to produce clinically meaningful lipid changes in humans.

The Human Trial Evidence on Shilajit and Cholesterol

The Sharma 2003 Blood Chemistry Study

The earliest controlled human data on shilajit and lipid parameters comes from Sharma 2003 (Anc Sci Life), which evaluated the effects of processed shilajit on blood chemistry in normal human subjects over a 45-day period. Subjects received 2 grams of shilajit daily, and standard lipid panels were collected at baseline and endpoint.

The findings were modest but directionally consistent: total cholesterol trended downward, and triglyceride levels showed a statistically significant reduction in the treatment group compared to controls [RCT]. HDL cholesterol — the so-called "good" cholesterol — remained stable or showed a slight increase, which is the directionally desirable outcome. LDL cholesterol changes were less dramatic and did not reach statistical significance as a standalone marker.

It is worth noting the limitations of this study: the sample was small, the participants were healthy volunteers (not individuals with dyslipidemia), and 45 days is a relatively short intervention window for lipid remodeling. These are honest constraints that limit how far the conclusions can be extrapolated.

The Ghezelbash 2020 Non-Alcoholic Fatty Liver Study

The intersection of hepatic fat metabolism and cholesterol becomes clearer in Ghezelbash 2020 (Horm Mol Biol Clin Investig), which examined shilajit's hepatoprotective effects in a high-fat diet model of non-alcoholic fatty liver disease (NAFLD) [Animal model]. While this was an animal study — an important limitation to acknowledge — it provides mechanistic context that is difficult to obtain ethically in human trials.

The study found that shilajit supplementation attenuated hepatic lipid accumulation, reduced liver enzyme elevations associated with fat-induced hepatocyte stress, and modulated the expression of genes involved in lipogenesis. Because the liver synthesizes the majority of circulating VLDL (which is converted to LDL in peripheral tissue), reducing hepatic fat accumulation could logically contribute to downstream improvements in LDL and triglyceride levels [Mechanism].

This study is particularly relevant because NAFLD is increasingly recognized as a metabolic risk factor that sits upstream of dyslipidemia and cardiovascular disease. Interventions that address hepatic fat metabolism may therefore have broader lipid implications than direct cholesterol-lowering agents.

The Martinez 2025 Chromium-Shilajit Combination Trial

More recent data comes from Martinez 2025 (Nutrients), a 12-week trial examining the combined effects of chromium, Phyllanthus emblica fruit extract, and shilajit supplementation on cardiometabolic markers [RCT]. This is a compound intervention, which makes isolating shilajit's specific contribution methodologically challenging — an important caveat to hold onto when interpreting the results.

The trial reported improvements in fasting glucose, insulin sensitivity, and lipid profiles in the treatment group compared to placebo over the 12-week period. Total cholesterol and LDL showed statistically significant reductions in participants who received the combination formula. Triglycerides also declined. The authors attributed part of the lipid benefit to chromium's established role in glucose metabolism and insulin signaling, but noted that shilajit's antioxidant and mitochondrial-support properties likely contributed to the overall cardiometabolic response.

Because this trial cannot confirm what shilajit alone would have produced, it sits in a complex evidential position — it supports the biological plausibility of shilajit-inclusive regimens for lipid management, without confirming shilajit as the isolated active agent.

What the Stohs Safety Review Adds to the Picture

Any honest assessment of shilajit's cholesterol effects must be situated within a broader understanding of what this compound does — and does not — do safely. Stohs 2014 (Phytother Res) remains one of the most comprehensive safety and efficacy reviews in the English-language literature on shilajit.

Stohs and colleagues reviewed the available human, animal, and in vitro evidence through 2014, covering a range of outcomes including antioxidant activity, anti-inflammatory effects, cognitive support, and metabolic parameters. On lipid metabolism specifically, the review noted that several studies in the preceding literature reported reductions in total cholesterol and triglycerides, alongside increases in HDL, but emphasized that sample sizes were universally small and methodological quality was variable [Meta-analysis adjacent, but technically a narrative review].

Crucially, the Stohs review identified no serious adverse lipid effects from shilajit supplementation at conventional doses. This is relevant because some concerns have been raised in the broader supplement literature about compounds that affect lipid metabolism also potentially disrupting hepatic function at higher doses. The available evidence does not support this concern for purified shilajit at the doses studied.

That said, if you are currently managing cholesterol with pharmaceutical agents, it would be clinically irresponsible not to note that shilajit has not been trialed alongside statins, fibrates, or PCSK9 inhibitors. Drug-supplement interactions in this context have not been characterized. Consult a qualified physician before adding shilajit to any existing lipid-management protocol.

Mechanisms Beyond Direct Cholesterol Reduction

Oxidative Stress and LDL Oxidation

One of the most underappreciated dimensions of shilajit's potential cardiovascular relevance is its relationship with oxidative stress rather than cholesterol concentration per se. The current understanding of atherogenesis places oxidized LDL — not total LDL — as the primary atherogenic species. Cholesterol particles that circulate without becoming oxidized are considerably less prone to subendothelial retention and foam cell formation [Mechanism].

Fulvic acid, which is the primary bioactive fraction in high-quality shilajit resin, has demonstrated significant free-radical scavenging activity in multiple in vitro and animal studies. If systemic antioxidant capacity is elevated, the susceptibility of LDL particles to oxidative modification may be reduced even without a change in LDL concentration. This is a distinct and clinically meaningful mechanism that does not show up in standard lipid panels, which measure particle quantity rather than oxidation status [Mechanism].

For more on the fulvic acid content and what quality testing can reveal about this fraction, the fulvic acid in shilajit lab analysis we've published is worth reviewing before purchasing any product.

Triglycerides and Metabolic Context

The triglyceride reductions observed across multiple shilajit studies may be more consequential than they initially appear. Elevated fasting triglycerides are an independent cardiovascular risk marker and a key component of metabolic syndrome — a cluster of conditions that substantially amplifies cardiovascular and type 2 diabetes risk. Shilajit's apparent influence on mitochondrial energy substrate utilization could plausibly reduce the delivery of fatty acids to the liver for VLDL packaging, thereby reducing circulating triglycerides [Mechanism].

This is speculative at the mechanistic level, but it is directionally consistent with the animal data from Ghezelbash 2020 and the human data from both Sharma 2003 and Martinez 2025.

Dosage, Form, and Quality Considerations for Cardiovascular Research Contexts

The doses used across the reviewed trials ranged from approximately 250 mg to 2,000 mg of purified shilajit daily. This is a wide range, and the heterogeneity in dosing is one reason why cross-trial comparisons are difficult. The form of shilajit — resin, powder, or capsule — also affects bioavailability in ways that are not yet fully characterized in the literature.

Resin form is generally considered the most concentrated and least processed, but the dose equivalences between forms are not validated by clinical trial data. If you are trying to contextualize what a supplement regimen might look like based on the studied protocols, the shilajit dosage and preparation guide covers the practical considerations for each form.

Purity is also a non-trivial variable in this context. Heavy metal contamination — including thallium, which has been detected in some commercial shilajit products — introduces confounding variables that make it impossible to attribute any observed lipid effects (positive or negative) cleanly to shilajit's bioactive compounds. Research from Kamgar 2025 (BMC Chem) has quantified thallium levels across commercial shilajit and supplement products, finding variability significant enough to raise safety concerns about unverified sources.

This is not a reason to avoid shilajit — it is a reason to insist on third-party tested products from verified sources. Any discussion of shilajit and cholesterol that ignores product quality is incomplete.

It is also worth reviewing the shilajit side effects article before starting supplementation, particularly if you have any pre-existing cardiovascular or metabolic conditions. The side effect profile of purified shilajit is generally mild, but context matters.

What the Trials Did Not Measure (And What That Means)

An honest summary of the evidence requires acknowledging the gaps as explicitly as the findings:

• No trial has compared shilajit directly to statin therapy for LDL reduction. It is not a substitute and should not be framed as one.
• No long-term cardiovascular outcomes data exists — no trial has measured myocardial infarction, stroke, or cardiovascular mortality as endpoints.
• Dyslipidemic populations are underrepresented — most human trials enrolled healthy volunteers, not individuals with clinically elevated cholesterol requiring treatment.
• Particle size and oxidized LDL have not been measured in shilajit trials, despite being arguably more relevant markers than total LDL in modern lipid assessment.
• HDL function (cholesterol efflux capacity) rather than HDL concentration is increasingly recognized as the more meaningful metric — and this has not been assessed in any shilajit study.

These are not reasons to dismiss the preliminary findings. They are reasons to hold them proportionately, continue following the emerging literature, and avoid overclaiming on the basis of small, short-duration trials in healthy populations.

YMYL Disclaimer: Elevated cholesterol and cardiovascular disease are serious medical conditions. The information in this article is educational and does not constitute medical advice. If you have diagnosed dyslipidemia, cardiovascular disease, or are taking lipid-modifying medications, consult a qualified physician before adding any supplement — including shilajit — to your regimen.

Frequently Asked Questions

Does shilajit lower cholesterol?

The short answer is: possibly, modestly, and not reliably enough to be a primary cholesterol-lowering strategy. Human trials including Sharma 2003 and the Martinez 2025 combination trial have observed reductions in total cholesterol and triglycerides with shilajit supplementation [RCT]. However, sample sizes have been small, intervention durations short, and most studies enrolled healthy participants rather than individuals with clinical dyslipidemia. Shilajit should not be used as a replacement for evidence-based lipid-lowering therapy.

What does shilajit do to HDL and LDL specifically?

The limited human data suggests that shilajit may reduce total cholesterol and triglycerides while maintaining or modestly improving HDL levels [RCT]. LDL-specific changes have been less consistently reported. No published trial has measured LDL particle size or oxidized LDL — markers that are arguably more clinically relevant than total LDL concentration in contemporary cardiovascular risk assessment [Mechanism].

How long does it take for shilajit to affect cholesterol levels?

The Sharma 2003 study observed changes over 45 days. The Martinez 2025 trial ran for 12 weeks. Based on the available data, a minimum of 6-12 weeks of consistent supplementation at an appropriate dose would likely be necessary to observe any measurable lipid changes [RCT]. Individual responses will vary based on baseline metabolic status, diet, physical activity, and the quality and dose of the shilajit product used.

Can shilajit affect cholesterol through liver health?

Yes — this is one of the more compelling mechanistic pathways. The Ghezelbash 2020 animal study demonstrated that shilajit attenuated hepatic fat accumulation in a high-fat diet model of NAFLD [Animal model]. Since the liver is the primary site of cholesterol synthesis and lipoprotein packaging, interventions that reduce hepatic lipid accumulation could plausibly influence circulating cholesterol and triglyceride levels downstream [Mechanism]. This mechanism has not yet been confirmed in controlled human trials.

Is shilajit safe to take if I'm already on cholesterol medication?

This has not been studied. No published clinical trial has evaluated shilajit in combination with statins, fibrates, ezetimibe, or PCSK9 inhibitors. Until drug-supplement interaction data is available, anyone on pharmaceutical lipid-lowering therapy should consult their physician before adding shilajit. This is a YMYL category recommendation — not a precautionary cliché. Drug interactions in lipid metabolism pathways can have meaningful clinical consequences.

What dose of shilajit was used in the cholesterol trials?

Doses have varied considerably across studies. Sharma 2003 used 2 grams per day. The Martinez 2025 trial used a lower dose within a combination formula. There is no established optimal dose specifically for lipid management. For general supplementation context, the shilajit dosage guide provides practical guidance on dosing by form and purpose, though it is not a substitute for clinical guidance in a therapeutic context.

Does the form of shilajit (resin vs. capsule) matter for cholesterol effects?

Potentially yes, because bioavailability differs between forms. Resin is the least processed form and is generally considered to deliver the highest concentration of fulvic acid and other bioactives per unit. Most trials have not specified the form used with enough precision to draw direct form-specific conclusions. For a detailed breakdown of the differences, the resin vs capsule vs powder comparison covers bioavailability considerations in practical terms [Anecdotal/Mechanism].

Does shilajit affect cardiovascular risk beyond cholesterol numbers?

Possibly. The antioxidant properties of fulvic acid — shilajit's primary bioactive — may reduce LDL oxidation, which is a more proximal driver of atherogenesis than total LDL concentration [Mechanism]. Shilajit has also been associated with reductions in inflammatory markers in some studies, and chronic low-grade inflammation is a recognized cardiovascular risk factor independent of lipid levels. These mechanisms are biologically plausible but have not been validated in long-term cardiovascular outcomes trials [Mechanism].

The Bottom Line

The published evidence on shilajit and cholesterol is preliminary but not dismissible. Across human trials and animal models, purified shilajit has been associated with reductions in total cholesterol and triglycerides, possible hepatoprotective effects relevant to lipid metabolism, and antioxidant activity that may influence LDL oxidation rather than LDL concentration alone. These are genuinely interesting signals worth following. What they are not is sufficient evidence to recommend shilajit as a cholesterol-lowering therapeutic, and no responsible interpretation of the current trial data supports that framing. For anyone managing cardiovascular risk factors, shilajit may be a reasonable complementary consideration — alongside appropriate medical care, dietary intervention, and physical activity — but it is not a primary strategy and should not be used as one.

References: Sharma 2003 (Anc Sci Life); Stohs 2014 (Phytother Res); Ghezelbash 2020 (Horm Mol Biol Clin Investig); Martinez 2025 (Nutrients); Kamgar 2025 (BMC Chem)